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An enhanced regimen as post-exposure
chemoprophylaxis for leprosy: PEP++
Liesbeth F Mieras1* , Anna T Taal1, Wim H van Brakel1, Emmanuelle Cambau2, Paul R Saunderson3,
W Cairns S Smith4, Cita Rosita S Prakoeswa5, Linda Astari5, David M Scollard6, Dejair Caitano do Nascimento7,
Jacques Grosset8, Hemanta K Kar9, Shinzo Izumi10, Laura Gillini11, Marcos C L Virmond7
and Marieke G G Sturkenboom12
Abstract
The ongoing transmission of Mycobacterium (M.) leprae reflected in a very slow decline in leprosy incidence, forces
us to be innovative and conduct cutting-edge research. Single dose rifampicin (SDR) as post-exposure prophylaxis
(PEP) for contacts of leprosy patients, reduces their risk to develop leprosy by 60%. This is a promising new
preventive measure that can be integrated into routine leprosy control programmes, as is being demonstrated in
the Leprosy Post-Exposure Programme that is currently ongoing in eight countries.
The limited (60%) effectiveness of SDR is likely due to the fact that some contacts have a preclinical infection
beyond the early stages for which SDR is not sufficient to prevent the development of clinical signs and symptoms
of leprosy. An enhanced regimen, more potent against a higher load of leprosy bacteria, would increase the
effectiveness of this preventive measure significantly.
The Netherlands Leprosy Relief (NLR) is developing a multi-country study aiming to show that breaking the chain of
transmission of M. leprae is possible, evidenced by a dramatic reduction in incidence. In this study the assessment
of the effectiveness of an enhanced prophylactic regimen for leprosy is an important component. To define the so
called PEP++ regimen for this intervention study, NLR convened an Expert Meeting that was attended by clinical
leprologists, public health experts, pharmacologists, dermatologists and microbiologists.
The Expert Meeting advised on combinations of available drugs, with known efficacy against leprosy, as well as on
the duration of the intake, aiming at a risk reduction of 80–90%. To come to a conclusion the Expert Meeting
considered the bactericidal, sterilising and bacteriostatic activity of the potential drugs. The criteria used to
determine an optimal enhanced regimen were: effectiveness, safety, acceptability, availability, affordability, feasibility
and not inducing drug resistance.
The Expert Meeting concluded that the enhanced regimen for the PEP++ study should comprise three standard
doses of rifampicin 600 mg (weight adjusted when given to children) plus moxifloxacin 400 mg given at four-
weekly intervals. For children and for adults with contraindications for moxifloxacin, moxifloxacin should be
replaced by clarithromycin 300 mg (weight adjusted).
Keywords: Post-exposure prophylaxis, Chemoprophylaxis, Intervention study, Leprosy, Rifampicin, Moxifloxacin,
Clarithromycin
* Correspondence: L.Mieras@Leprastichting.nl
1Netherlands Leprosy Relief, Amsterdam, Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.




This is a report of an Expert Meeting to propose an en-
hanced chemoprophylaxis regimen to be tested in a ran-
domised controlled intervention study for contacts of
leprosy patients. The meeting was held in November
2016, in Amsterdam, the Netherlands, and was attended
by clinical leprologists as well as epidemiologists/public
health leprosy experts, pharmacologists, dermatologists
and microbiologists. All participants are co-authors of
this paper. This report deals only with considerations re-
lated to the selection of agents to be used in a prophy-
laxis study, and does not describe a protocol for the field
study. The protocol will be discussed in a future
publication.
Background on post-exposure prophylaxis for leprosy
In the past decade a very slow decline in leprosy inci-
dence and evidence of ongoing transmission of M. leprae
has been observed. To achieve elimination of leprosy in
terms of zero new cases, transmission has to be stopped
first. Predictions made, using the individual-based math-
ematical model SIMCOLEP, show that leprosy is likely
to remain a problem in high endemic regions without
additional control measures [1]. One of the main chal-
lenges is the long incubation period that is around five
years on average [2]. Clinical diagnosis is most com-
monly based on clinical signs and symptoms: a defined
skin lesion with loss of sensation, thickened nerves with
definite loss of sensation or weakness of hands/feet,
presence of visible deformities and/or a positive skin
smear. The need for treatment is decided by a clinician
[3].
The presence of M. leprae in nasal swabs from asymp-
tomatic community members, as determined by PCR or
by the presence of antibodies against leprosy bacilli, is
dynamic over time [4, 5]. However, existing links be-
tween asymptomatic community members testing posi-
tive and people with clinical disease seem to suggest the
possibility of transmission by subclinical cases [6]. Fur-
ther evidence is needed to show whether asymptomatic
carriers can in fact transmit M. leprae. Contacts of
people affected by leprosy are known to be at higher risk
of developing the disease [7, 8]. Therefore providing
post-exposure prophylaxis (PEP) to contacts of leprosy
patients may help to stop transmission and will contrib-
ute to reducing the number of new leprosy cases. Several
chemoprophylactic regimens have been demonstrated to
be effective. For example, dapsone given once or twice
weekly for at least two years reduced the risk of develop-
ing leprosy by 60% and acedapsone, given every ten
weeks for seven months, reduced this risk by 49% [9–
11]. A single dose of rifampicin (SDR) given to contacts
of leprosy patients also showed to reduce the risk of
developing leprosy by approximately 60% in the first two
years [12]. A combination of rifampicin, ofloxacin and
minocycline (ROM) has shown protective efficacy simi-
lar to that observed in studies using rifampicin alone,
but it was not more bactericidal [13, 14].
PEP with SDR has been adopted as national policy in
several countries with a very low leprosy burden, such as
Cuba (since 2002), Morocco (since 2014) and Samoa
(since 2015). PEP was implemented as a sub-national
policy in recent years in Indonesia, Nepal and India [15].
Furthermore, the leprosy post-exposure prophylaxis
(LPEP) programme is currently ongoing in eight coun-
tries: Tanzania, India, Nepal, Sri Lanka, Myanmar, Brazil,
Cambodia and Indonesia. This operational research
programme is carried out in partnership with the Minis-
tries of Health and members of the International Feder-
ation of Anti-Leprosy Associations (ILEP), with support
of the Novartis Foundation. The purpose of the LPEP
programme is to learn more about the most effective
and acceptable ways of integrating prophylactic treat-
ment into routine leprosy control programmes and to
study the impact of SDR on the case detection rates of
leprosy in the study districts [16]. Preliminary results
show that the level of acceptance of SDR among leprosy
patients and their contacts is very high and that the inte-
gration of a single dose prophylaxis in routine leprosy
control is feasible [17].
However, SDR is only 60% effective in preventing lep-
rosy among contacts of new patients [12]. At least one
likely reason for the limited effectiveness of chemo-
prophylaxis with SDR is that manifestations of the dis-
ease cannot be prevented with one single dose of
rifampicin in contacts with a preclinical infection beyond
the very early stages. This hypothesis is supported by the
aforementioned limited effectiveness of SDR, especially
in blood-related household contacts in the COLEP trial,
among whom SDR only prevented leprosy in less than
30% [12]. Based on scientific reasoning, it is likely that
the effectiveness of the current SDR regimen could be
increased if contacts of leprosy patients with pre-clinical
disease would be treated with an appropriate enhanced
prophylactic regimen. A second reason for the limited
effectiveness of SDR is the short half-life of rifampicin in
the blood (just over 3 h) and the fact that only one dose
is administered. Using an antibiotic with a longer
half-life in plasma, either on its own or in combination
with rifampicin, in repeated doses is likely to enhance
the bactericidal effect on M. leprae.
Background on the PEP++ research project
NLR has prepared a study protocol for a multi-country
study on stopping the transmission of M. leprae, in
which the assessment of the effectiveness of an en-
hanced prophylactic regimen for leprosy is an important
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component. NLR convened this Expert Meeting to de-
velop a consensus proposal for such an enhanced regi-
men of which the effectiveness would be compared to
SDR as part of this study. The request was to choose a
combination of available drugs, with known efficacy
against leprosy, and a duration of such an enhanced
prophylactic regimen, aiming at a risk reduction of 80–
90%, 20–30% more effective than SDR. We call this the
PEP++ regimen.
The PEP++ research project will test the enhanced
regimen using a cluster-randomised trial design to com-
pare the effectiveness of the enhanced post-exposure
prophylaxis regimen with that of SDR in close contacts
(household contacts, neighbours and social contacts)
who have a higher risk of developing leprosy [8]. Con-
tacts will be followed-up after taking SDR or PEP++ to
determine the difference in case detection rate in both
groups. Besides an assessment of the effectiveness of the
regimen, the PEP++ research project will include a per-
ception of leprosy study, an acceptability study and a
cost-benefit analysis. The research protocol will be de-
scribed in detail in a separate publication.
In short, the PEP++ research project aims to provide
evidence that a combination of a large-scale application
of the current SDR and PEP++ will be able to prevent
the development of leprosy disease among contacts and,
as a consequence, stop the transmission of M. leprae in
previously high-endemic areas. A novel cluster-based
blanket implementation of SDR will be used, including
all inhabitants of an area in which a cluster of leprosy
patients is identified. Clusters in the participating dis-
tricts will be identified using geographic information sys-
tem (GIS) technology. The interventions will be
supported by optimised leprosy case detection and treat-
ment services, including but not limited to health sys-
tems strengthening, contextualised community
education on leprosy, stigma reduction interventions
and involvement of leprosy-affected persons in various
roles in their communities.
Main text
Possible drugs for enhanced chemoprophylaxis regimen
The mechanism of chemoprophylaxis is either killing of
the causative organisms before the onset of pathology or
killing of the pathogen allowing sub-clinical disease to
heal or both. In leprosy, because the incubation period is
very long, both mechanisms may be involved, though
the latter may be more likely. The ideal enhanced regi-
men would reduce the risk of developing leprosy consid-
erably more than 60% without inducing selection of
drug-resistant mutants in leprosy, or other infectious
diseases such as tuberculosis, which would lead to a
higher risk of relapse and transmission of drug-resistant
leprosy.
The Expert Meeting agreed that the PEP++ regimen
should be comprised of drugs that are available in lep-
rosy endemic countries and are approved by the United
States Food and Drug Administration (FDA) and the
European Medicines Agency (EMA). Bedaquiline, oxazo-
lidinone and nitro-dihydro-imidazo-oxazoles were ex-
cluded, because they have not been registered in the
countries where the PEP++ research project is planned
to take place (India, Brazil and Indonesia) or have not
been used for the treatment of leprosy. The standard
multidrug therapy (MDT) for leprosy, introduced in
1982, is a combination of dapsone and rifampicin for
paucibacillary (PB) leprosy, and dapsone, rifampicin and
clofazimine for multibacillary (MB) leprosy. MDT is as-
sociated with very low relapse rates in patients who
complete treatment [18]. Other drugs with known effi-
cacy against leprosy are rifapentine, fluoroquinolones
(such as ofloxacin, levofloxacin and moxifloxacin), mino-
cycline and clarithromycin [19].
In order to select the most potent drugs for the regi-
men, the Expert Meeting considered the bactericidal ac-
tivity (ability to kill replicating bacteria), the sterilising
activity (ability to kill non-replicating bacteria – per-
sisters) as well as the bacteriostatic activity (ability to
prevent bacterial growth) of the potential drugs. The ef-
fectiveness of the drugs discussed below has been evalu-
ated on established infections in mouse footpads.
Rifampicin, routinely used for the treatment of lep-
rosy, blocks the RNA-polymerase which is the first step
of protein synthesis and prevents the replication of M.
leprae without killing on the spot actively-replicating
bacteria. However, blocking the synthesis of proteins that
are involved in the basic metabolism of non-replicating
bacteria (persisters) prevents their survival, which means
that rifampicin is actually a key sterilising drug. Shepard
et al. [20] demonstrated a complete loss of infectivity in
mice of inocula from five lepromatous patients treated
for 7 days with a daily dose of 600 mg of rifampicin. Ri-
fampicin is well tolerated and when used as a single or
repeated monthly dose very few side effects are seen,
apart from discoloration of urine [21].
Rifapentine is a rifamycin derivative like rifampicin,
but has a longer plasma half-life of 14 to 18 h compared
to rifampicin with only 3 h. The killing power of M.
leprae with a single dose rifapentine, determined by the
proportional bactericidal technique in the mouse foot-
pad model [22], was 99.6% in contrast to the bactericidal
activity of rifampicin which was 92.1% [23]. Also, M.
leprae shows a lower minimum inhibitory concentration
(MIC) for rifapentine than for rifampicin [24]. Further-
more, fewer doses are needed to prevent relapse
(12 weeks) in mouse models of tuberculosis, compared
to 24 weeks for rifampicin, because the sterilising effect
of rifapentine is stronger [25]. However, the newly
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developed molecular viability assays indicate that the
bactericidal effect of rifamycin derivates may be less
rapid than the mouse footpad methods suggested [26].
In conclusion, rifapentine would be a good choice as
chemoprophylactic drug for leprosy because of its strong
anti-mycobacterial potential. Nevertheless, experience
with rifapentine in leprosy patients is limited and it is
currently unavailable in most countries. It is accepted by
the FDA for use in TB in the USA, but not by the EMA
in Europe.
Even though the working mechanism of clofazimine
against M. leprae is not fully understood, it appears to
involve interference with the proton motive force and
therefore bacterial adenosine triphosphate (ATP) pro-
duction by membrane interaction with the respiratory
chain and/or phospholipids [27]. Clofazimine would be a
potential candidate for the PEP++ regimen, because it is
already used in MB MDT. Nevertheless, it has two big
disadvantages: it lacks early bactericidal activity, taking
weeks of daily use to build an effective tissue concentra-
tion, and it causes discoloration of the skin after about
one month of treatment. Especially, the latter is a major
concern for some people, because it is noticed by others
and can take a long time to disappear. It is not known
whether giving clofazimine intermittently is as effective
as a daily dose, nor is it known whether intermittent use
would completely prevent skin discoloration.
Dapsone is a bacteriostatic drug, used for leprosy
treatment since 1945. It inhibits the bacterial nucleic
acid synthesis, the building blocks of bacterial DNA.
The infectiousness of M. leprae, tested by inoculation of
mice, reduces to 1% after 90 days of dapsone treatment
[28]. However, its extensive use as monotherapy for lep-
rosy before the introduction of MDT, has contributed to
the development of dapsone resistant leprosy strains.
In the group of fluoroquinolones, moxifloxacin has
the best bactericidal activity against M. leprae in a mur-
ine model [23]. It has a plasma half-life of around 12 h.
The fluoroquinolones inhibit bacterial DNA synthesis by
targeting the enzymatic activities of DNA gyrase, neces-
sary for DNA replication. The bactericidal efficacy of
moxifloxacin against M. leprae in the mouse footpad
model was 92.1% [23]. Moxifloxacin is not routinely
used as a drug for leprosy patients, but in a clinical
proof-of-concept trial in eight multibacillary leprosy pa-
tients, moxifloxacin proved highly effective. In the trial
patients, a single 400 mg dose of moxifloxacin resulted
in significant killing (P ≤ 0.006) of M. leprae, ranging
from 82 to 99%, with a mean of 91% [29]. Skin lesions
improved rapidly; subtle improvement in some patients
was observed after a single 400 mg dose of moxifloxacin.
In all eight patients definite improvement was observed
with an additional week of daily moxifloxacin (day 14).
Moxifloxacin is currently used for treatment of leprosy
in a clinical trial in India (Kar, personal communication,
November 2016).
Unlike some other fluoroquinolones, moxifloxacin
demonstrated to have low propensity for causing photo-
toxic reactions in animal studies. But other findings in
safety studies in animals (e.g. arthrotoxicity in juvenile
animals and CNS toxicity) that have led to restrictions
in the use of quinolones in general, have also been ob-
served with moxifloxacin. Similar to other fluoroquino-
lones, moxifloxacin has been shown to cause lesions in
the cartilage of the weight-bearing joints of immature
animals. It should therefore not be used in children, or
pregnant women unless the benefits outweigh the risks.
Even though, there is lack of correlation between find-
ings in juvenile animals and those in children [30]. Pre-
clinical studies, in which high doses of moxifloxacin
were used, demonstrated the potential to induce convul-
sions. Caution is required with patients having an in-
creased risk for tachyarrhythmia because it induces QT
interval prolongation [31]. However, a meta-analysis
done to determine its effectiveness and safety for tuber-
culosis treatment concluded that the combination of
moxifloxacin with the recommended regimen for the
treatment of TB, with a daily dose of 400 mg given for
at least 2 months, does not cause additional adverse
events [32].
The working mechanism of ofloxacin is similar to that
of moxifloxacin, but the bactericidal effect proved to be
much less than moxifloxacin in the mouse footpad
model (60.2% vs. 92.1%) and less adverse effects were
observed [23]. The plasma half-life of around 6 h is
much shorter than that of moxifloxacin (around 12 h)
and therefore the duration of the effect is also much
shorter [33, 34].
Minocycline is a semisynthetic tetracycline. Its bac-
tericidal activity was shown in a trial where a single
200 mg dose of minocycline was given to eight leproma-
tous patients. This decreased the number of patients
with viable M. leprae, as demonstrated in mouse foot-
pads (six of the eight patients) [35]. However, the bac-
tericidal effectiveness of minocycline against M. leprae is
less than that of rifampicin [36]. As with other tetracy-
clines, it is contraindicated in children because it leads to
discoloration of developing teeth, and may cause hyper-
sensitivity (DRESS syndrome) in some patients [37, 38].
The bactericidal effect of clarithromycin for M. leprae
was 74.9% in the mouse footpad model [23]. Clinical tri-
als indicated that it is rapidly bactericidal for M. leprae
in humans [39]. It is not routinely used in the treatment
of leprosy, but it can safely be given to children. It was
used as a prophylactic drug for leprosy in a trial in
Indonesia conducted among healthy elementary school
children in high-endemic areas in East Java province
(Prakoeswa, personal communication, November 2016).
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An enhanced chemoprophylaxis regimen was given to
children with high antibody titres (anti-PGL IgM) for
leprosy: rifampicin 300 mg/day and clarithromycin
250 mg/day for the first ten days, followed by three
months of intermittent two-weekly doses of rifampicin
300 mg and clarithromycin 250 mg. During the 5-year
follow-up period the children were screened annually for
signs/symptoms of leprosy and blood was taken to
measure anti PGL-1 IgM titres. Although no control
group was included in the study and a substantial pro-
portion of the children was lost to follow-up, several im-
portant observations were made. Rifampicin and
clarithromycin were well tolerated, no major adverse
events were seen, none of the children was diagnosed
with leprosy during the follow-up period, and 87% of the
children had a decrease in the anti PGL-1 IgM titres.
Qualifications of an optimal enhanced chemoprophylaxis
regimen
An enhanced chemoprophylaxis regimen should meet
several criteria. It should be highly effective, much more
than the current SDR regimen, safe without substantial
side effects, acceptable to people who are not ill, avail-
able, affordable, feasible to administer on a large scale,
and should not induce drug resistance in leprosy or TB
bacteria. Safety, effectiveness and affordability are com-
monly used to select chemoprophylaxis regimens, drug
resistance is to be avoided in all use of antibiotics, the
other criteria are more specific for the use of chemo-
prophylaxis for leprosy [40].
The first criterion is effectiveness. The new regimen
should be sufficiently bactericidal to treat people har-
bouring higher numbers of M. leprae likely to be present
in those with subclinical infection. Potentially, it should
be capable of curing early MB leprosy. Given that the
current SDR PEP regimen is 60% effective, the new regi-
men should be substantially more effective to be worth-
while, e.g. offering a protective effectiveness of 80 to
90%. For an increased preventive effect, a long-acting
antibiotic and/or repeated administration is necessary.
Repeating doses have a greater bactericidal effect than a
single dose.
The second criterion is safety. The regimen will be
given to healthy individuals as a preventive measure.
People may be reluctant to take multiple drugs or mul-
tiple doses when they do not feel sick. It is therefore of
greatest importance to avoid any adverse event to the
extent possible. Contraindications for any of the drugs
in the regimen should be checked carefully, before pro-
viding the regimen.
The third criterion is acceptability. The regimen
should be easily acceptable for healthy contacts, because
they are not motivated to take the drugs by being ill.
The tablets or capsules should be easy to swallow and
for smaller children the availability of the drug as a
syrup would be preferred. Also, the schedule for the in-
take of the drugs should be simple enough to adhere to
and the number of repeating doses should be limited.
Furthermore, the regimen should ideally not induce any
side effects, such as nausea, dizziness, headaches or skin
discoloration.
The fourth criterion is availability of the drug. The
drug should be available in the countries where the PEP
++ research project is taking place at an affordable rate
(fifth criterion).
The sixth criterion, feasibility to administer the regi-
men on a large scale is a combination of the above cri-
teria, but also encompasses logistical aspects. It should
be possible to widely distribute the drugs in adequate
amounts. Storage requirements for the drugs should be
simple and the shelf life sufficiently long.
The seventh criterion is that the prophylaxis should
not induce drug resistance in M. leprae or M. tubercu-
losis. The probability of emergence of resistance depends
on the mycobacterial load, the potency of drugs
(pharmacodynamics) and the number of drugs (less in
combinations of ≥2 drugs). It is known that repeated
doses of one drug will increase the risk of the develop-
ment of resistance. To prevent this, a combination of
drugs is preferred when giving multiple doses [41]. Anti-
microbial resistance is well known in leprosy. Rifampicin
resistance was first described in 1976 and fluoroquino-
lones resistance in 1997 [42, 43]. The antimicrobial re-
sistance proportion was estimated to be 8%, in a first
prospective open survey conducted by a WHO surveil-
lance network in the period 2009–2015 [44].
Specific interventions to address concerns about resist-
ance, such as surveillance, will be established during the
PEP++ research project. Additional logistical consider-
ations must be taken into account in the development of
the final field protocol. These considerations are beyond
the scope of this report and will be detailed in a future
publication.
Possible drug combinations for enhanced
chemoprophylaxis
Theoretically, one or two months of MDT treatment
could be used as prophylactic treatment. Two months of
MDT or one month of MDT ending with a monthly
dose of rifampicin would appear to be a feasible regi-
men. The efficacy of MDT is known, it uses the same
drugs for adults and children, it is available and it is ac-
cepted in all leprosy endemic counties. However, if
standard MDT is given as preventive treatment, contacts
and community members may perceive this as leprosy
treatment and think that people taking this medication
are leprosy patients. Moreover, on the basis of safety
considerations, dapsone should not be included in the
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regimen since it occasionally causes a potentially fatal
hypersensitivity syndrome [45], while its bacteriostatic
properties are unlikely to have an additional beneficial
effect. Clofazimine is not preferred because of the late
bactericidal activity and the discoloration of the skin it
causes. This is not easily accepted by people, as it is as-
sociated with being on treatment for leprosy.
ROM has been used to treat single lesion leprosy.
Compared to rifampicin, ofloxacin and minocycline have
been shown to be less bactericidal in mouse models [46,
47]. ROM is no more bactericidal than rifampicin alone
[46]. A combination of rifampicin with a more powerful
bactericidal drug would therefore be preferred for opti-
mal efficacy of a chemoprophylactic regimen.
Rifampicin remains a good candidate as component of
the enhanced regimen, although its short half-life is a
limitation. The wide use of single-dose rifampicin in the
LPEP project has shown to be safe (no serious adverse
events have been reported to date), acceptable, available
and affordable [17]. The Expert Meeting advised to com-
bine rifampicin with moxifloxacin, the most bactericidal
of the possible drugs for an enhanced regimen, with a
longer half-life and good pharmacodynamic properties.
It was agreed that the combination is likely to increase
the protective effect of the chemoprophylaxis substan-
tially, especially when repeated doses are given. Import-
antly, combining two antibiotics would reduce the
likelihood of inducing resistance [48]. Fluoroquinolones
in general and moxifloxacin specifically have been used
as chemoprophylaxis for TB, also in children; no serious
adverse events were reported [49–51]. However, fluoro-
quinolones are known to have potentially toxic side ef-
fects, especially in children, which need to be considered
when they are used as prophylaxis instead of treatment
of disease. The Expert Meeting therefore advised to re-
place moxifloxacin by clarithromycin when giving the
chemoprophylaxis to children (< 16 years) and adults
with a contraindication for moxifloxacin. Giving the
combination of rifampicin and clarithromycin to all con-
tacts, children as well as adults, is not preferred, because
of the stronger bactericidal effect of moxifloxacin. Both
rifampicin and clarithromycin can be given to children
in syrup form.
To determine the frequency and duration of the use of
the regimen, the Expert Meeting had the following
considerations:
When rifampicin was introduced as component of
MDT treatment, a monthly dose was recommended in
view of the good therapeutic efficacy and the fact that
this was better tolerated than a weekly dose and the
lower costs compared to daily or weekly treatment [52].
The Expert Meeting strongly advised that the enhanced
regimen should also be given supervised to ensure com-
pliance and repeatedly to increase the bactericidal effect.
From a logistical point of view, a regimen that will be
given daily for seven days is difficult to administer as an
observed dose. An interval of one week or less is likely
to cause more side effects [53, 54]. A monthly dose is
therefore preferred and more feasible as it is easier to be
supervised. Giving three doses instead of one single dose
was advised to increase the probability of killing more
bacilli in an active metabolic state.
The contraindications used for SDR (pregnancy, liver
or renal disorders, signs or symptoms of leprosy, signs
or symptoms of TB, known allergy to rifampicin) would
also apply to the enhanced regimen [16]. In addition
people with known cardiac or neurological disease, espe-
cially people suffering from seizures should be given
clarithromycin instead of moxifloxacin.
Conclusion
The Expert Meeting concluded that an enhanced
prophylactic regimen against leprosy would comprise
multiple doses of rifampicin and moxifloxacin, since this
would combine the two most bactericidal drugs avail-
able. Because moxifloxacin is not recommended in chil-
dren rifampicin plus clarithromycin was considered the
preferred regimen for child contacts and also for adults
with moxifloxacin-specific contraindications.
For the PEP++ intervention study, the Expert Meeting
proposed an enhanced regimen comprising three doses
of rifampicin 600 mg (weight adjusted when given to
children) plus moxifloxacin 400 mg given at four-weekly
intervals (day 1, day 29 and 57) over 8 weeks. For chil-
dren and for adults with contraindications for moxiflox-
acin, moxifloxacin should be replaced by clarithromycin
300 mg (weight adjusted).
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